Principal Financial Group Inc Apellis Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

  • $160 Billion
  • Q2 2024

A detailed history of Principal Financial Group Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 12,885 shares of APLS stock, worth $484,862. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,885
Previous 84,604 84.77%
Holding current value
$484,862
Previous $4.97 Million 90.07%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024
SELL
$38.07 - $59.71 $2.73 Million - $4.28 Million
-71,719 Reduced 84.77%
12,885 $494,000
Q1 2024

Apr 29, 2024
BUY
$55.39 - $72.47 $3.36 Million - $4.4 Million
60,741 Added 254.54%
84,604 $4.97 Million
Q4 2023

Feb 07, 2024
SELL
$37.14 - $64.82 $115,876 - $202,238
-3,120 Reduced 11.56%
23,863 $1.43 Million
Q3 2023

Nov 02, 2023
SELL
$23.65 - $89.22 $566,961 - $2.14 Million
-23,973 Reduced 47.05%
26,983 $1.03 Million
Q2 2023

Aug 07, 2023
BUY
$76.68 - $93.31 $1.95 Million - $2.37 Million
25,416 Added 99.51%
50,956 $4.64 Million
Q1 2023

May 09, 2023
SELL
$46.59 - $66.96 $2.21 Million - $3.18 Million
-47,442 Reduced 65.01%
25,540 $1.68 Million
Q4 2022

Feb 09, 2023
BUY
$43.24 - $61.04 $2.07 Million - $2.93 Million
47,936 Added 191.39%
72,982 $3.77 Million
Q3 2022

Nov 09, 2022
SELL
$44.76 - $69.66 $9,131 - $14,210
-204 Reduced 0.81%
25,046 $1.71 Million
Q2 2022

Aug 10, 2022
BUY
$35.07 - $59.21 $33,176 - $56,012
946 Added 3.89%
25,250 $1.14 Million
Q1 2022

May 09, 2022
BUY
$35.46 - $54.12 $60,140 - $91,787
1,696 Added 7.5%
24,304 $1.24 Million
Q4 2021

Feb 09, 2022
SELL
$30.74 - $49.16 $224,432 - $358,917
-7,301 Reduced 24.41%
22,608 $1.07 Million
Q3 2021

Nov 09, 2021
BUY
$31.4 - $69.84 $30,520 - $67,884
972 Added 3.36%
29,909 $986,000
Q2 2021

Aug 10, 2021
SELL
$40.9 - $64.9 $27,484 - $43,612
-672 Reduced 2.27%
28,937 $1.83 Million
Q1 2021

May 10, 2021
SELL
$40.8 - $57.39 $49,572 - $69,728
-1,215 Reduced 3.94%
29,609 $1.27 Million
Q4 2020

Feb 08, 2021
BUY
$30.79 - $57.2 $179,567 - $333,590
5,832 Added 23.34%
30,824 $1.76 Million
Q3 2020

Nov 06, 2020
SELL
$25.89 - $33.65 $29,825 - $38,764
-1,152 Reduced 4.41%
24,992 $754,000
Q2 2020

Aug 05, 2020
BUY
$24.8 - $38.49 $409,894 - $636,162
16,528 Added 171.88%
26,144 $854,000
Q1 2020

May 12, 2020
BUY
$17.91 - $44.33 $5,695 - $14,096
318 Added 3.42%
9,616 $258,000
Q4 2019

Feb 05, 2020
BUY
$22.1 - $30.8 $11,735 - $16,354
531 Added 6.06%
9,298 $285,000
Q3 2019

Nov 13, 2019
BUY
$24.09 - $32.18 $2,890 - $3,861
120 Added 1.39%
8,767 $211,000
Q2 2019

Aug 12, 2019
BUY
$18.0 - $25.34 $155,646 - $219,114
8,647 New
8,647 $219,000

Others Institutions Holding APLS

# of Institutions
299
Shares Held
113M
Call Options Held
5.21M
Put Options Held
691K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $4.13B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email